Therawis Pharma GmbH is a privately held, profitable oncology-specialized company with offices located in Munich, Germany, and was founded in April 2014. We provide european-wide support in medical & clinical trial development for therapeutics and diagnostics. The Therawis team has significant expertise and an outstanding track record for life cycle management of IVD devices.
The overall strategic vision of Therawis Pharma GmbH is to combine highly innovative and novel diagnostics with effective therapeutics in oncology:
“The theranostic approach “.
Therawis Diagnostics GmbH is a privately held oncology- and virology-focused company with offices located in Munich, Germany, and was founded together with clinicians and scientists of the Technical University of Munich in September 2015. Therawis Diagnostics GmbH develops and aims to commercialize a comprehensive portfolio of diagnostics in oncology and virology.
Our vision is to deliver to the market our proprietary exosome platform as the next generation liquid biopsy diagnostics in oncology, virology and immunology enabling easier biomarker discovery and diagnostic performance through its unprecedented selectivity and sensitivity.